Literature DB >> 10664280

Recent status of primary sclerosing cholangitis in Japan.

H Takikawa1.   

Abstract

Patients with primary sclerosing cholangitis (PSC) in Japan have two peaks in age distribution, one in their twenties and the other in their fifties and sixties. PSC patients in Japan have different characteristics from those in other countries: there is a higher incidence of eosinophilia (27%) and positivity for anti-nuclear antibody (30%), less frequent complication with inflammatory bowel diseases (IBD; 21%), and more frequent complication with chronic pancreatitis (15%). In younger patients in Japan (those aged less than 40 years), the incidence of positivity for anti-nuclear antibody was lower (20% vs 38% P < 0.05), complication with IBD was more frequent (39% vs 9% P < 0.01), complication with chronic pancreatitis was less frequent (4% vs 22% P < 0.01), and damage to both the intra- and extrahepatic bile ducts was more frequent (89% vs 56% P < 0.01) than in older patients (those aged 40 years or more). These findings suggest that younger PSC patients in Japan have characteristics similar to those of patients in other countries, and that in Japan older PSC patients have a different pathogenesis from that of younger patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10664280     DOI: 10.1007/s005340050129

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  4 in total

Review 1.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

2.  Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

Authors:  Ryuichi Kita; Seigo Takamatsu; Toru Kimura; Hiroyuki Kokuryu; Yukio Osaki; Naomi Tomono
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

3.  Resected case of eosinophilic cholangiopathy presenting with secondary sclerosing cholangitis.

Authors:  Fumihiko Miura; Takehide Asano; Hodaka Amano; Masahiro Yoshida; Naoyuki Toyota; Keita Wada; Kenichiro Kato; Tadahiro Takada; Junichi Fukushima; Fukuo Kondo; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

4.  Sclerosing pancreatitis presenting as a periampullary tumour.

Authors:  A K Sahajpal; C M Vollmer; A Pollett; S Gallinger
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.